Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer
Deborah Y. Moss,Connor Brown,Andrew Shaw,Christopher McCann,Nikita Lewis,Aaron Phillips,Sarah Gallagher,William J. McDaid,Andrew Roe,Aisling Y. Coughlan,Brenton Cavanagh,Callum Ormsby,Fiammetta Falcone,Rachel McCole,Scott Monteith,Emily Rogan,Matilda Downs,Sudhir B. Malla,Alexandra J Emerson,Letitia Mohammed-Smith,Shaun Sharkey,Peter F. Gallagher,Arindam Banerjee,Sufyan Pandor,Brett Greer,Christopher Elliott,Aideen Ryan,Philip D. Dunne,Vicky Coyle,Ian G. Mills,Simon S. McDade,Owen Sansom,Triona Ni Chonghaile,Daniel B. Longley,Melissa J. LaBonte,Emma M. Kerr
DOI: https://doi.org/10.1101/2024.09.12.611189
2024-09-13
Abstract:Therapy resistance is attributed to over 80% of cancer deaths per year emphasizing the urgent need to overcome this challenge for improved patient outcomes. Despite its widespread use in colorectal cancer (CRC) treatment, resistance to 5-fluorouracil (5FU) remains poorly understood. Here, we investigate the transcriptional responses of CRC cells to 5FU treatment, revealing significant metabolic reprogramming towards heightened mitochondrial activity. Utilizing CRC models, we demonstrate sustained enhancement of mitochondrial biogenesis and function following 5FU treatment, leading to resistance in both in vitro and in vivo settings. Furthermore, we show that targeting mitochondrial metabolism, specifically by inhibiting Complex I (CI), sensitizes CRC cells to 5FU, resulting in delayed tumour growth and prolonged survival in preclinical models. Additionally, our analysis of patient data suggests that oxidative metabolism signatures may predict responses to 5FU-based chemotherapy. These findings shed light on mechanisms underlying 5FU resistance and propose a rational strategy for combination therapy in CRC, emphasizing the potential clinical benefit of targeting mitochondrial metabolism to overcome resistance and enhance patient outcomes.
Cancer Biology